Navigation Links
CMC Biologics Adds 2,000 Liter Single-Use Bioreactor at its Copenhagen Manufacturing Facility

COPENHAGEN, Denmark and SEATTLE, Sept. 1, 2011 /PRNewswire/ -- CMC Biologics today announced the completion of the installation of a 2,000 liter single-use bioreactor (2,000L SUB) at its manufacturing facility in Copenhagen. The Thermo Scientific HyClone SUB, one of several SUBs CMC Biologics has in its manufacturing facilities in Copenhagen and Seattle, will begin shake-down runs and is expected to be ready for GMP contract manufacturing by December 2011.


According to Gustavo F. Mahler, Ph.D., Global Chief Operations Officer of CMC Biologics, "The expansion of the facility to include the 2,000L SUB will allow us to meet increasing demand for producing biologicals for Phase III and into market supply. The advantages for CMC Biologics and our customers are clear: reduced project times, reduced risk of cross-contamination resulting in increased process reliability and reduced batch manufacturing costs that will allow CMC Biologics to be even more competitive." Mahler added, "We have worked closely with Thermo Fisher Scientific to bring this project in on time and on budget."

"It has been our pleasure to work with CMC Biologics. With their leadership in contract biopharmaceutical manufacturing and applying single-use systems, it is not surprising that our first 2,000L SUB in Europe is being installed at their Danish facility," stated Brandon Pence, Global Director of Marketing, Cell Culture and Bioproduction, Thermo Fisher Scientific.

Forthcoming Single-Use Technology Events

Webinar: Practical and Theoretical Implications of Single Use Bioreactor Technology

Date: Thursday, September 15, 2011

Start Time: 14:15 GMT+1

Duration: 1 hour

For more information:

ISPE Nordic Conference: Single Use Technology in Pharmaceutical Production

Date: October 5, 2011

Location: Uppsala, Sweden

For more information:

Single-Use Technology Seminar

Co-sponsored by Applikon Biotechnology, BioProcess International, CMC Biologics, and Thermo Fisher Scientific

Date: Tuesday and Wednesday, October 25-26, 2011

Location: Clarion Hotel in Copenhagen, Denmark

This event will provide an opportunity to view the 2,000L SUB at CMC Biologics' facility in Copenhagen during a facility tour and reception on Tuesday evening.

For more information:

About CMC Biologics

CMC Biologics ( is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes. For more information, please visit

SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
2. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
5. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
6. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
7. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
8. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
9. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
10. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
11. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
Post Your Comments:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):